Vincerx Pharma, Inc is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx was founded by a group of highly experienced drug development professionals with an established track record for getting drugs rapidly approved (eg, Accelerated Approval). Our vision is to address the unmet medical needs of patients with cancer with a diverse pipeline of targeted medicines. Our small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. Our antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are next-generation ADC compounds addressing known and novel oncology targets that we believe could deliver a greater safety and efficacy profile than current ADC compounds. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.
PTEFb Inhibitor Program
Next-Generation Adc Technology
Antibody-drug conjugates (ADCs) are an established therapeutic approach in oncology used to selectively deliver potent cytotoxins directly to tumor cells, with the goal of maximizing toxicity in tumor cells, while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells…